聚乙二醇干扰素α-2a治疗核苷(酸)类似物经治者初探  

Exploring of pegylated interferon α-2a treatment of nucleos(t)ide analogue-experienced patients with chronic hepatitis B

作　　者：张鸿飞[1] 陈新月[2] 谢尧[3] 贺永文[4] 

机构地区：[1]解放军第三○二医院青少年肝病诊疗与研究中心,北京100039 [2]首都医科大学附属北京佑安医院国际医疗部,100069 [3]首都医科大学附属北京地坛医院肝炎一科,100015 [4]华中科技大学附属协和医院传染科,武汉430022

出　　处：《传染病信息》2012年第6期339-342,共4页Infectious Disease Information

摘　　要：核苷(酸)类似物经治慢性乙型肝炎患者的处理是目前临床的热点与难点问题之一。国内外小规模的研究结果显示,聚乙二醇干扰素α-2a治疗核苷(酸)类似物经治患者有助提高停药后持久应答,对于各类核苷(酸)类似物经治患者,如何采用更有效的聚乙二醇干扰素α-2a治疗方案,实现更高持久免疫控制,值得探讨。Nowadays, management of nucleos（t）ide analogue （NA）-experienced patients with chronic hepatitis B becomes one of the focuses and difficult issues. Several domestic and international pilot studies have revealed that the addition of pegylated interferon α-2a to NA therapy is associated with a high sustained post-treatment response. For NA-experienced patients, treatment strategies that can achieve a higher sustained immune control rate with pegylated interferon α-2a are worthy of being explored.

关 键 词：乙型肝炎 慢性 核苷类 抗病毒药 聚乙烯二醇类 

分 类 号：R512.62[医药卫生—内科学]